RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

Nicholas J. Robert, Véronique Diéras, John Glaspy, Adam M. Brufsky, Igor Bondarenko, Oleg N. Lipatov, Edith A. Perez, Denise A. Yardley, Stephen Y.T. Chan, Xian Zhou, See Chun Phan, Joyce O'Shaughnessy

Research output: Contribution to journalArticlepeer-review

711 Scopus citations

Fingerprint Dive into the research topics of 'RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences